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Abstract
Introduction
Dengue is a rapidly emerging vector-borne Neglected Tropical Disease, with a 30-fold
increase in the number of cases reported since 1960. The economic cost of the illness is
measured in the billions of dollars annually. Environmental change and unplanned urbaniza-
tion are conspiring to raise the health and economic cost even further beyond the reach of
health systems and households. The health-sector response has depended in large part on
control of the Aedes aegypti and Ae. albopictus (mosquito) vectors. The cost-effectiveness
of the first-ever dengue vaccine remains to be evaluated in the field. In this paper, we exam-
ine how it might affect the cost-effectiveness of sustained vector control.
Methods
We employ a dynamic Markov model of the effects of vector control on dengue in both vec-
tors and humans over a 15-year period, in six countries: Brazil, Columbia, Malaysia, Mexico,
the Philippines, and Thailand. We evaluate the cost (direct medical costs and control pro-
gramme costs) and cost-effectiveness of sustained vector control, outbreak response and/
or medical case management, in the presence of a (hypothetical) highly targeted and low
cost immunization strategy using a (non-hypothetical) medium-efficacy vaccine.
Results
Sustained vector control using existing technologies would cost little more than outbreak
response, given the associated costs of medical case management. If sustained use of
existing or upcoming technologies (of similar price) reduce vector populations by 70–90%,
the cost per disability-adjusted life year averted is 2013 US$ 679–1331 (best estimates) rel-
ative to no intervention. Sustained vector control could be highly cost-effective even with
less effective technologies (50–70% reduction in vector populations) and in the presence of
a highly targeted and low cost immunization strategy using a medium-efficacy vaccine.
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Discussion
Economic evaluation of the first-ever dengue vaccine is ongoing. However, even under very
optimistic assumptions about a highly targeted and low cost immunization strategy, our
results suggest that sustained vector control will continue to play an important role in mitigat-
ing the impact of environmental change and urbanization on human health. If additional ben-
efits for the control of other Aedes borne diseases, such as Chikungunya, yellow fever and
Zika fever are taken into account, the investment case is even stronger. High-burden
endemic countries should proceed to map populations to be covered by sustained vector
control.
Author summary
Transmitted by the Aedes mosquito, dengue affects more than 100 countries and is rapidly
emerging as the leading vector-borne disease. There has been a 30-fold increase in the
number of cases reported since 1960. The cost of the illness to the health system and to
society at large is estimated at several billions of dollars annually. The health sector
response has depended in large part on controlling mosquito populations during out-
breaks. Recently, the first-ever dengue vaccine received regulatory approval for use in sev-
eral countries. However, its roll-out and long-term impact still needs to be evaluated in
the field. In this paper, we examine how the introduction of this vaccine might alter the
investment case for sustained effort to control mosquitoes. To our knowledge, this is the
first economic evaluation of mosquito control in the era of the dengue vaccine. We model
the cost and effects of mosquito control in Brazil, Columbia, Malaysia, Mexico, the Philip-
pines, and Thailand. We evaluate the cost-effectiveness of mosquito control in the pres-
ence of a vaccine that does not offer full protection to all individuals. Our results suggest
that sustained mosquito control will continue to be cost-effective, even if roll-out of the
current vaccine is highly targeted and low-cost. These results support current global poli-
cies and strategies for the prevention and control of dengue.
Introduction
Dengue is a rapidly emerging disease endemic in more than 100 countries, with evidence of
transmission reported in 128 countries [1]. Today, hundreds of thousands of severe dengue
cases arise every year, including about 20 000 deaths. The economic cost of the illness in the
Americas and South-East Asia is already measured in the billions of dollars annually, including
costs such as work and school days lost [2][3][4]. In the Western Pacific, between half and
two-thirds of affected households have incurred debt as a result of the care they received [5]
[6]. Environmental change and unplanned urbanization are conspiring to raise the cost of den-
gue infection further beyond the reach of health systems and households. In 2014, Southern
China suffered the worst outbreak of dengue fever in more than two decades; Japan saw
autochthonous transmission in its first outbreak of the disease since 1945 [7,8].
In the absence of a fully effective vaccine or any treatment, dengue control has depended
solely on the control of the Aedes aegypti and Aedes albopictus vectors. Current strategies
include personal protection or biological, chemical, and environmental measures. In 2006, the
second edition of the Disease Control Priorities Project (DCP2) put the cost per disability-
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adjusted life year (DALY) averted by vector control at US$ 1992–3139 (presumably in 2005 US
$). Since then, the dengue economics literature suggests lower cost-effectiveness ratios ranging
from 2005 US$ 227 (2013 US$ 344) per DALY averted by larval control in Cambodia to 2009
US$ 615–1267 (2013 US$ 802–1652) per DALY averted by adult mosquito control in Brazil [9]
[10].
A recent systematic review concluded that results were not easily comparable due to differ-
ences in methodological assumptions, and that combined control strategies remained largely
unexplored [11].
The authors note that “there is growing interest in combining vector control with vaccina-
tion once a dengue vaccine becomes widely available, which recognizes that one intervention
is insufficient to effectively reduce the burden of disease.” They cite results from studies with
malaria and lymphatic filariasis that support the impact of simultaneously targeting vectors
and pathogens.
Prior to 2015, the absence of a dengue vaccine did not preclude efforts to model the condi-
tions under which such an immunization strategy might be cost-effective [12][13][14][15].
Prospects for a viable immunization strategy have since improved, though not without compli-
cations [16]. In December 2015, the first-ever dengue vaccine, known as chimeric yellow fever
virus-dengue virus tetravalent dengue vaccine or CYD-TDV (Dengvaxia), was approved for
use in the Philippines. A strategy consisting of one year of catch-up vaccinations targeting chil-
dren 9–15 years of age, followed by regular vaccination of 9-year-old children, may be cost-
effective at costs up to $72 from a health-care perspective and up to $78 from a societal per-
spective [17]. However, a review of the results of eight independent modelling groups con-
cluded that “the potential risks of vaccination in areas with limited exposure to dengue as well
as the local costs and benefits of routine vaccination are important considerations” [18].
It has been argued that, even in the era of a vaccine, the health sector response to dengue is
expected to continue to depend in large part on vector surveillance and control [19,20]. In this
paper, we undertake a comprehensive review and synthesis of the evidence on the cost and
cost-effectiveness of dengue control interventions from the health system perspective. We
appraise the cost-effectiveness of sustained vector control (including outbreak response) in the
presence of a (hypothetical) highly targeted and low-cost immunization strategy using a (non-
hypothetical) medium-efficacy vaccine. We consider also outbreak response and/or medical
case management alone. We model a zero-cost or null scenario in which no intervention at all
is implemented (not even medical case management).
We generate cost and cost-effectiveness estimates for six middle-income countries: Brazil,
Columbia, Malaysia, Mexico, the Philippines, and Thailand. These countries were the focus of
recent systematic reviews of epidemiological trends and make up an estimated 15% of the
global burden of dengue [21]. Our approach is deliberately conservative. As the focus of the
study is assessing the cost-effectiveness of vector control in the age of a dengue vaccine, a con-
servative approach means making generous assumptions about the efficacy and cost of the vac-
cine and ungenerous assumptions about the efficacy and cost of vector control.
Methods
A dynamic compartmental model using Markov chains was built using the open source soft-
ware R. The model builds on that of Luz et al. (2011) [9]. We introduce outbreaks, urbaniza-
tion, and climate change and update the model within a probabilistic sensitivity analysis (PSA)
framework. We generate 1000 simulations for each of 780 weekly cycles (15 years), represent-
ing the years 2016–2030, following a model burn-in period of 500 cycles. Best estimates and
95% uncertainty intervals (UIs) are obtained by the mean and the 2.5th and the 97.5th
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percentiles across all iterations. For cost-effectiveness, we report uncertainty using cost-effec-
tiveness acceptability curves and a Net Monetary Benefit (NMB) approach.
Baseline model with outbreaks, urbanization and climate change
The model runs two probabilistic Markov chains in parallel–one each for vector and human
populations. The model is depicted in Supporting Information S1 Fig. In every cycle, the prob-
ability of a vector being infected with the dengue virus, thus moving from susceptible (SV) to
infected (IV), is dependent on the number of infected humans in the previous cycle. Likewise
the probability of a susceptible human (SH) being infected is dependent on the number of
infected vectors. However, susceptible humans are separated into two categories, denoted SH1
and SH2, representing susceptibility to first and second infections respectively, or DH1 and
DH2.
New-borns enter the model in state NBH. New-borns have maternal immunity and there-
fore remain immune from dengue infection for a period of time. As maternal immunity
wanes, new-borns enter the susceptible population (SH1). When a human recovers from their
first infection (DH1), they enter a state of recovery from first infection (RH1). In state RH1,
humans are assumed to have cross-immunity and cannot contract dengue, after which they
become susceptible to a second infection (SH2) from a different dengue serotype. If a human
contracts dengue for a second time (DH2)–that is, contracts a different dengue serotype–they
may progress to severe dengue (SDH). In SDH, there is an elevated probability of mortality
(Death). If an individual recovers from DH2 or SDH they are assumed to no longer be suscepti-
ble (RH2).
The baseline model therefore allows for the effect of herd immunity (and loss thereof). As
individuals move through the states, contracting dengue, the proportion of individuals that are
still susceptible decreases and the population as a whole builds up herd immunity. If new indi-
viduals entering the model are less likely to contract dengue for reasons other than acquired
immunity (for example, the introduction of sustained vector control, as described below),
herd immunity wanes over time, at the rate of population replacement, and the probability of
transmission increases.
We model symptomatic or apparent cases only. The number of cases of asymptomatic or
unapparent cases is potentially much larger [22]. Several studies have demonstrated high levels
of asymptomatic infection in endemic countries [23][24], leading to more severe primary
symptomatic infections in those individuals [25]. Recent evidence suggest that asymptomatic
viraemic individuals can infect Aedes aegypti [26], although there is no evidence as to whether
these are then able to infect humans. We have not estimated the effect of asymptomatic infec-
tion in our models due to the limited literature available.
The (biting) female vector population is assumed to be proportional to the human popula-
tion. The average number of female vectors per host is 1.0–6.0, with a sine function of period
length 2π and a standard deviation of 20% [27]. In addition to seasonal variation, there is also
a probability in every cycle of switching to an outbreak model of the vector population. In
defining dengue outbreaks, previous studies have used moving means of the number of
human cases and standard deviations of those means, but these differ between countries and
even at subnational level [28].
We model outbreaks as a 100–200% increase in the vector population over a period of 2–9
weeks [29]. The increase is relative to the baseline vector population of any given intervention.
This choice allows us to more directly model the effect of outbreak response. The Markov
model is structured such that the increase in vector population results, through a higher proba-
bility of infective bites, in a higher number of human cases. During the burn-in period, the
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probability of outbreak is set such that frequency of outbreak is once every 3–5 years [30]. This
range is consistent with the country reviews, although somewhat conservative with regard to
Malaysia [31].
Urbanization is reflected in part by increases in the new-born and susceptible human popu-
lations, given by the crude birth rate and the urban population growth rate minus the crude
birth rate, respectively. We model the combined effect of both unplanned urbanization and cli-
mate change after the burn-in period by allowing for the frequency of outbreak to drop to as
low as once every 2 years (that is, frequency follows a triangular distribution with 2 and 5 as
minimum and maximum, respectively, and 3 as the most likely value). Alternatively, we could
have modelled climate change as an increase in the average number of female vectors per host
and/or standard deviation of the sine function. However, this alternative would suggest pre-
dictable rather than unpredictable variation over time in the number of vectors and, by exten-
sion, a different type of outbreak response than we have defined below.
A list of the baseline model parameters and distributions of the probabilities underpinning
the model are listed (with sources) in Table 1. Additional parameters for the intervention mod-
els are listed in Table 2, and described here. Whenever possible, we used country-specific
parameter values; in practice, these were mainly available for population at risk estimates, unit
cost estimates, and basic health statistics such as population, birth rates, death rates (adult and
child), life expectancy, and urban growth rates. Of note, we used country-specific probabilities
of death among severe dengue cases receiving care. These were based on country-reported
data, and varied considerably: from a low of 0.65% in Mexico to a high of 7% in Brazil [32].
Effect of medical case management
In the presence of medical management, the fatality rate of severe dengue cases is assumed to
be 0.7–7% (range of best estimates from the six countries). The fatality rate is the same regard-
less of whether there is vector control or immunization. In the absence of any medical case
management, however, the fatality rate for severe dengue is assumed to be 5–20% [40][41].
Effect of sustained vector control and outbreak response
Recent reviews reveal that many existing vector control technologies have not been robustly
evaluated for impact on reducing human dengue cases [57,58]. By technology, we refer to any
combination of strategies and intervention tools that have been costed in the economics litera-
ture; these include biological (e.g. copepods), chemical (e.g. insecticides) and environmental
(e.g. screens) interventions. To our knowledge, only one study has measured the epidemiologi-
cal effect of such vector control technologies. A randomized controlled trial (RCT) of commu-
nity mobilization for dengue prevention demonstrated a lower risk of infection with dengue
virus in children (relative risk reduction 29.5%, 95% confidence interval 3.8% to 55.3%) and
fewer reports of dengue illness (24.7%, 1.8% to 51.2%) [59].
Several trials have, however, evaluated entomological impact. The above-mentioned RCT
found a 51.7% (36.2% to 76.1%) reduction in the number of pupae per person (pupae found/
number of residents). An earlier systematic review and meta-analysis found that the most
effective method (integrated vector control) resulted in decreases of 67–88% (best estimates)
in the following indices: the number of containers with larvae per 100 houses (Breteau index),
the percentage of water containers positive for larvae or pupae (Container index) and the per-
centage of houses with water containers containing larvae or pupae (House index) [60].
The value of larval indices has been challenged, however; pupal indices may be more valu-
able given lower pupal mortality and higher correlation with adult densities [61]. All evidence
considered, the systematic review concluded that “dengue vector control is effective in
An economic evaluation of vector control in the age of a dengue vaccine
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Table 1. Baseline model parameters, with distributions and sources.
Parameter Distribution Mean (with standard
deviation) or range or
confidence interval (CI)
Sources
Humans
Population at risk in base year Triangular Country-specific Most likely value is based on [33]; minimum value based on
[34]; maximum value is based on [35]
Crude birth rate of population (annual) Deterministic Country-specific [36]
Growth rate of urban population
(annual)
Deterministic Country-specific [37]
Crude death rate (annual) Deterministic Country-specific [38]
Probability of developing severe dengue
after secondary infection (weekly)
Beta 0.048 (0.013) [39], consistent also with [12], but we conservatively assume a
zero probability after primary infection
Probability of death among severe
dengue patients, without case
management (weekly)
Uniform Min = 0.05 or country-specific
Max = 0.20
[40][41], with floor set at maximum of: 0.05 or country-specific
probability of death among severe dengue patients, with case
management
Probability of death among severe
dengue patients, with case
management (weekly)
Beta Country-specific [32]
Average age of patients who die from
severe dengue
Deterministic 30 Conservative assumption, since the majority of deaths tend to
occur among children, aged <15 years.[21]
Average life expectancy of general
population
Deterministic Country-specific [42]
Rate of loss of maternal antibodies
(weekly)
Gamma 0.055 (0.041) [12]
Average duration of infectiousness,
primary and secondary (weeks)
Deterministic 1 [12]; duration of illness differs (see below).
Average duration of recovery from
primary infection, including cross
immunity (years)
Lognormal 1.88 (95% CI 0.88–4.31) [43], gives a weekly probability of 0.011, conservative relative
to [12] which used rate of 0.0055 per day or a weekly
probability of 0.038
Relative probability of being susceptible
to a second infection
Triangular Min = 0.1
Most likely = 0.66,
Max = 0.75
Maximum is comparable to [12] which put the relative
probability of being susceptible to ith infection at (5-i)/4
Dengue disability weight Beta 0.197 (0.004) [44], conservative relative to [9] and [45], and same as [12]
Severe dengue disability weight Beta 0.545 (0.004) [44], conservative relative to [9] and [45], same as [12]; we
assumed a correlation of 0.999 with non-severe dengue so
that dengue disability weight does not exceed the severe
dengue disability weight
Average duration of dengue illness
(years)
Beta 0.019 (0.007) [12]
Average duration of severe dengue
illness (years)
Beta 0.034 (0.009) [12]; assumed correlation of 0.999 with non-severe dengue
Discount rate for health Uniform 0–3% [46]
Vectors
Average number of female vectors per
host
Uniform 1.0–6.0 [27], with assumed sine function of period length 2π and a
standard deviation of 20%
Increase in vector populations during
outbreak
Uniform 100–200% [29]
Outbreak duration (weeks), no outbreak
control
Uniform 2.0–9.0 Assumption
Outbreak periodicity (years) Triangle Min = 2
Most likely = 3
Max = 5
Conservative assumption relative to [30]
Death rate of adult vector (weekly) Lognormal 0.255 (0.010) [47], which is between the values used by [12] for young and
old adults
(Continued )
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reducing vector populations, particularly when interventions use a community-based, inte-
grated approach, which is tailored to local eco-epidemiological and sociocultural settings and
combined with educational programmes to increase knowledge and understanding of best
practice”.
We opted to model the effect of vector control as a reduction of the vector population (or,
more generally, a reduction of the vector population capable of transmitting the virus). Ento-
mological effects may vary significantly between settings, not least because the choice of vector
control technology is country- if not community-specific [62]. We therefore considered two
broad categories of vector control technology: a medium-efficacy technology that reduces vec-
tor populations by 50–70%; and a high-efficacy technology that reduces vector populations by
70–90%. We acknowledge that such reductions in adult vectors may not have been conclu-
sively demonstrated for long-term use of existing technologies.
These above reductions are applied to periods of outbreak also, such that sustained vector
control limits the increase in vector populations during the initial phases of the outbreak,
before the outbreak response is deployed. We define sustained vector control as vector control
activities undertaken routinely throughout the year, usually monthly, regardless of changes in
the number of vectors or human cases. Outbreak response activities, in comparison, are under-
taken only in response to spikes in the number of vectors or human cases and only for as long
as those spikes last. During outbreaks, increases in vector populations still occur in the pres-
ence of vector control, but from a lower baseline level.
Table 1. (Continued)
Parameter Distribution Mean (with standard
deviation) or range or
confidence interval (CI)
Sources
Biting rate (bites per day) Lognormal 0.561 (0.129) [48], conservative relative to [12], which used 0.7; conservative
assumption of correlation of -0.5 with vectors per host
Probability of transmission: vector to
human (per bite by an infected vector)
Beta 0.572 (0.083) [48], conservative relative to [12], which used 0.9
Probability of transmission: human to
vector (per bite of an infected human)
Beta 0.493 (0.067) [48]
Resource use and costs
Proportion of cases hospitalized, non-
severe dengue (primary hospital)
Beta 0.14 (0.03) [49]
Proportion of cases hospitalized, severe
dengue (secondary hospital)
Deterministic 1.00 [50]
Duration of hospital stay, non-severe
dengue (bed days)
Gamma 3.84 (0.64) [5][51]
Ratio of duration of hospital stay, severe
dengue to non-severe dengue
Deterministic 1.5 [52]
Ambulatory visits for a hospitalized case
(number)
Gamma 4.42 (0.81) [53] [51] [54]
Ambulatory visits for a non-hospitalized
case (number)
Gamma 3.68 (0.76) [51] [53] [54], with assumed correlation of 0.999 with
hospitalized cases
Unit cost of hospital bed day, primary
hospital (2013 US$)
Lognormal Country-specific See Table 3
Unit cost of hospital bed day, specialist
hospital (2013 US $)
Lognormal Country-specific See Table 3; assumed correlation of 0.999 with primary
hospital
Unit cost of ambulatory clinic visit (2013
US$)
Lognormal Country-specific See Table 3
Discount rate for costs Uniform 3–6% [46]
https://doi.org/10.1371/journal.pntd.0005785.t001
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In the baseline model of outbreak, the vector population remains high for 2–9 weeks. The
effect of outbreak response is modelled by a switch of the vector population to pre-outbreak
levels after a lag of 1–2 weeks–the minimum time assumed to be required to detect the increase
in vector populations and deploy the outbreak response. Since we are assuming that any sus-
tained vector control programme includes also an outbreak response component, this same
effect is modelled for both sustained vector control and outbreak response alone. This assump-
tion is optimistic with regard to outbreak response and therefore conservative with regard to
demonstrating the cost-effectiveness of sustained vector control relative to outbreak response.
In the absence of sustained control, vector populations return to baseline values, whereas in
the presence of sustained control, vector populations return to a level determined by the vector
control technology (e.g. 70–90% below baseline values, in the case of the high efficacy technol-
ogy). We assume that when sustained vector control and outbreak response are introduced, it
is the susceptible (rather than infected) vector population that is immediately reduced. The
number of infected vectors decreases more gradually (over their 28-day life span). This
assumption is pessimistic with regard to vector control and therefore conservative with regard
to demonstrating the cost-effectiveness of vector control versus immunization.
Effect of immunization
The first-ever dengue vaccine has now been licensed for use in persons aged 9–45 by countries
in Asia and Latin America and is under regulatory review by others. Phase III clinical trials of
CYD-TDV (Dengvaxia) have measured efficacy over 25 months from the first dose [63][64].
Pooled results (age 9) suggest efficacy of 38% (3–63%) among seronegatives and 78% (65–
Table 2. Additional intervention model parameters, with distributions and sources.
Parameter Distribution Mean (with standard deviation)
or range or confidence interval
(CI)
Source
Effects
Reduction in vector population,
medium technology vector control
Uniform 50–70% (8)(31)
Reduction in vector population, high
technology vector control
Uniform 70–90%
Outbreak length (weeks), sustained
vector control and/or outbreak
response
Uniform 1–2 Conservative assumption relative to [30]
Immunization coverage (annual) Uniform Country-specific Minimum is 9–14 year-old population in first year of
implementation (7.8–12.9% of total population in the six
countries); 9 year-old population thereafter (1.3–2.2%); up to a
maximum of 80% of seropositive and susceptible population
Vaccine efficacy (seropositive) Beta 82%
(95% CI 67–90%)
[55], pooled result for 9 years of age; we assume that 100% of
those vaccinated in any given year are seropositive
Costs
Sustained vector control (per person
per month, 2013 US$)
Lognormal Country-specific See Table 3
Vector control during outbreak only
(per person per week, 2013 US$)
Triangular Country-specific [53], with adjustments using proportion of labour in costs and
GDP per capita to determine the minimum, maximum and most
likely values
Surveillance for vector control (per
person per week, 2013 US$)
Triangular Country-specific [56], with adjustments using proportion of labour in costs and
GDP per capita to determine the minimum, maximum and most
likely values
Immunization (per person
immunized, 2013 US$)
Deterministic 20 Conservative assumption
https://doi.org/10.1371/journal.pntd.0005785.t002
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86%) among seropositives [16]. Unfortunately, these same trials reveal high rates of hospitali-
zation among those who were vaccinated when seronegative. This result suggests that the
immunization strategy should target the seropositive population [55].
In our model, we consider an optimistic scenario in which the immunization strategy is
perfectly effective in targeting the susceptible seropositive population (further described
below). The effect of immunization is modelled as a probability among individuals susceptible
to a second infection (SH2) of moving directly to the state of recovery from a second infection
(RH2). The same percentage reductions are applied to both outbreak and non-outbreak cycles
because outbreaks are modelled as changes in vector population rather than in serotype
distribution.
Population targeted for vector control
The entire at risk human population is targeted for vector control. The broadest definition of
the at-risk human population includes the urban population of the six countries. We also con-
sidered the subset living in urban slum areas. Poor urban communities typically have environ-
mental characteristics that facilitate Aedes spp. breeding, including presence of refuse deposits
and containers for water storage [65][66]. We also extracted from DengueMap a list of all loca-
tions from which alerts of dengue cases or deaths had been issued in 2013 [67]. We obtained
the latitude and longitude coordinates for these locations using the geocode program of the R
package mapproj. We then merged this dataset with the g-econ database [33].
We counted populations living within gecon-coded areas satisfying at least one of the fol-
lowing two conditions: 1) population density of more than 250 per km2 (non-rural settings);
AND 2) average minimum temperature of no less than 5 degrees Celsius AND an average
maximum temperature of no more than 36 degrees Celsius; AND 3) gross domestic product
(GDP) per capita (2005 purchasing power parity) of less than US$ 10 000 (excludes areas with
a level of development equivalent to a high income country); OR occurrence of a dengue alert
within the 1-degree latitude by 1-degree longitude cell. These cut-offs were based on studies
identified in a recent systematic review of dengue risk mapping models [68].
In PSA, the susceptible human population was represented by a triangular distribution
using g-econ, urban slum and urban populations as the most likely, minimum and maximum
values, respectively.
Population targeted for immunization
Mathematical models suggest that, to achieve significant reduction in the disease burden,
immunization is most effective if it includes only individuals that have been already exposed to
at least one dengue virus [69]. Some countries have decided to roll out immunization by tar-
geting specific age groups, such as all 9–14 year olds in the first year and then all (new) 9 year
olds in the second year onwards. Targeting strategies may be adapted to local settings. In the-
ory, age or other individual characteristics could be selected to either minimize the number of
seronegative people or maximize the number of seropositive people vaccinated.
We assume optimistically that the susceptible seropositive population is so effectively tar-
geted that 0% of the people that receive the vaccine are seronegative (100% are seropositive).
In other words, we assume that targeting strategies are perfectly effective in avoiding vaccine-
enhanced disease in vaccinated seronegative people. Furthermore, we assume that 70–80% of
the population that is seropositive (and still susceptible to second infection) is contained in the
population of people that are targeted over a period of 52 weeks. Of these, 80–90% are (again,
optimistically) assumed compliant with vaccination (comparable to yellow fever vaccination
coverage among children in Brazil).
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It bears emphasizing here that the objective of this paper is to assess the cost-effectiveness
of vector control in the presence of a (hypothetical) highly targeted and low-cost vaccination
strategy using a (non-hypothetical) medium-efficacy vaccine; it is not to assess the cost-effec-
tiveness of the medium efficacy vaccine itself.
Cost of medical case management
The cost of medical management of dengue cases is based on the utilization of general health
services only, or the “hotel cost” of hospital bed days and ambulatory visits excluding any labo-
ratory tests or drugs. The hospitalization rate, duration of hospitalization, and number of
ambulatory visits are provided in Table 1. We assume a hospitalization rate of 14% for non-
severe dengue and 100% for severe dengue (references are provided in Table 1). Hospitalized
non-severe cases are hospitalized in primary hospitals, and severe cases are hospitalized in spe-
cialist hospitals. Unit costs (best estimates and standard errors) were obtained using data and
methods from WHO-CHOICE [70]. These unit cost estimates are summarized in Table 3. All
symptomatic cases were assumed to receive medical management in all scenarios, regardless of
whether there was sustained vector control, outbreak response and/or immunization.
Cost of sustained vector control and outbreak response
We conducted a search of the literature on the cost of sustained vector control interventions
and identified eight studies with primary data, from 12 countries, considering different biolog-
ical, chemical, and environmental measures. A subsequent systematic review revealed no addi-
tional studies [11]. We extracted data on costs as well as populations or households covered.
Costs were converted to per capita terms and inflated to 2013 US$ using GDP deflators. These
unit costs were then modelled in a multivariate log-log regression on population covered and
GDP per capita. More than 50% of the variation in unit cost between the studies was explained
by these two variables alone, driven by a strongly negative relationship with population. In
addition to economies of scale, it is likely that higher cost biological and environmental mea-
sures were only implemented at smaller scale, in targeted communities. A plot of the data and
regression model results are available in Supporting Information S2 Fig and Supporting Infor-
mation S1 Table.
We calculated means and standard errors for the predictions for the six countries consid-
ered in this study, using their urban populations and GDP per capita. For each country, 1000
values of (log) unit cost were drawn from a normal distribution, and then exponentiated.
These unit cost estimates are summarized in Table 3. The best estimates are in the range of
about 2013 US$ 0.04–0.05 per person per month–similar to the cost of larviciding and/or
Table 3. Country-specific unit cost estimates (best and 95% uncertainty interval), 2013 US$.
Country Ambulatory clinic visit Hospital bed day, primary Hospital bed day, specialist Sustained vector control
(per capita per month)
Best Low High Best Low High Best Low High Best Low High
BRA 7.32 1.66 23.55 52.74 20.25 117.37 63.56 25.36 138.18 0.050 0.026 0.087
COL 48.64 9.50 142.11 193.25 75.75 405.19 233.30 85.03 501.79 0.057 0.033 0.091
MEX 37.73 8.52 116.51 338.60 129.77 736.02 411.36 156.78 878.56 0.054 0.029 0.095
MYS 27.43 5.96 79.04 239.75 91.71 521.26 299.40 114.71 600.06 0.060 0.034 0.100
PHL 9.87 2.13 30.02 58.84 23.36 125.25 70.85 27.64 154.62 0.042 0.022 0.074
THA 18.29 3.53 54.42 141.55 55.27 289.73 169.24 65.69 370.75 0.055 0.033 0.088
Brazil (BRA), Colombia (COL), Mexico (MEX), Malaysia (MYS), Philippines (PHL) and Thailand (THA).
https://doi.org/10.1371/journal.pntd.0005785.t003
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adulticiding programs described in studies from Brazil, Cambodia, Venezuela, and Thailand.
The confidence intervals are wide, however, with highs of up to 2013 US$ 0.06–0.09 allowing
for smaller scale biological and environmental measures. These unit costs are similar to those
described in studies from Guatemala, Kenya, Mexico, Myanmar, and the Philippines, pub-
lished prior to 2013. No costing studies have been undertaken for technologies under develop-
ment using Release of Insects with Dominant Lethality (RIDL) or Wolbachia symbiont
infection of vectors.
The cost of outbreak response was taken from a study from Panama [53]. That study found
that the cost of vector control during an outbreak, including larviciding and adulticiding, was
about 2005 US$ 0.035 per person per week. The Panama costs are conservative relative to a
more comprehensive costing of outbreak response in Cuba, including health education and/or
replacement of defective water tanks [71][72]. Similarly, the Panama costs are conservative rel-
ative to environmental and/or chemical interventions triggered by case reports in Malaysia
and Thailand [73][74]. We considered adjustments for our six countries using the proportion
of labour in costs (71%) and GDP per capita relative to that of Panama in the year of the study.
Minimum, most likely, and maximum values were obtained considering adjustments for GDP
per capita only, or GDP per capita and the labour proportion, or no adjustment at all.
We assumed that a sustained vector control programme would implement extraordinary
outbreak response interventions in the midst of an outbreak; therefore, during an outbreak,
the total cost of sustained vector control includes the cost of both the sustained vector control
and outbreak response interventions. To the cost of both sustained vector control and out-
break response alone we also added the cost of sustained surveillance, based on a study from
Brazil, at a cost of 2013 US$ 0.014 per person per week. Again we generated country-specific
minimum, most likely, and maximum values using the proportion of labour in costs (39%)
and relative GDP per capita [56].
Cost of immunization
Since the cost of a future vaccine is unknown, the cost per person vaccinated was assumed to
be about 2013 US$ 20. This unit cost is assumed to include the cost of screening for seroposi-
tivity, or whatever the cost of the perfectly effective targeting strategy, as well as administration
of the vaccine itself. It is purposefully optimistic. An earlier study considered a range of US$
10–300 per unit for the cost of vaccine production alone [12]. In most countries, US$ 20 is less
than the cost of the 1–3 outpatient visits that would be required for administration alone
(Table 3). It is also considerably lower than the maximum of the median willingness-to-pay
results (US$ 70) from Vietnam, Thailand, and Colombia [75].
Results
Effects
The number of cases of symptomatic dengue in the baseline model (medical case management
alone) is depicted in Fig 1, for each of the six countries. The waves represent seasonal variation.
Outbreaks are not visible in the best estimate or uncertainty intervals obtained from the 1000
simulations but are visible in individual simulations, only one of which is depicted for illustra-
tion. We compare these baseline model results to recent published estimates to ensure that we
are not overstating the potential effects of intervention in terms of cases or DALYs averted
[22]. For most countries our estimates in year one are towards the lower bound of those pub-
lished estimates, and for all countries the uncertainty intervals overlap. Our estimates trend
slightly upward over time. Note that the published estimates take into account current (but
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variable) efforts to control dengue whereas the estimates presented in Fig 1 are for our baseline
model (medical case management alone).
The effect of sustained vector control on the total number of dengue cases (including severe
cases) is depicted over time in Fig 2. Different sustained vector control technologies (medium
and high efficacy) are considered, and compared to the baseline (medical case management
only). Vector control technologies of low efficacy (<50% reduction in vector populations)
have limited longer-term impact on transmission, and are therefore not depicted.
Initially, medium- and high-efficacy vector control technologies result in a significant
decrease in the number of cases. The combination of vector control and acquired immunity
push the basic reproduction number to below one. In time, the number of susceptible people
waxes and herd immunity wanes. With high-efficacy vector control, the period of low trans-
mission lasts from four to seven years, varying between countries. Differences between
Fig 1. Weekly number of dengue cases with no vector control or immunization (case management only), our base model compared to published
estimates of apparent cases, best estimates and 95% UIs. The black line and grey bands represent the best estimates and uncertainty intervals for the
number of dengue cases as projected by our base model; the dotted black line represents the number of dengue cases in a single, randomly selected
iteration of the model; the blue bands represent uncertainty intervals for apparent cases, as published by Bhatt et al. (2013)
https://doi.org/10.1371/journal.pntd.0005785.g001
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countries are explained by differences in the country-specific parameters, namely birth rates,
death rates, and urban growth rates, which together determine the rate at which susceptible
people are introduced into the model.
The number of cases of severe dengue follows a similar pattern, but with a somewhat lon-
ger-term effect of high efficacy vector control, as can be verified in Supporting Information S3
Fig.
The effect of highly targeted immunization using a medium-efficacy vaccine on the number
of dengue cases is depicted over time in Fig 3, alone and in combination with sustained vector
control (high efficacy). The total number of dengue cases is largely unaffected by immuniza-
tion alone, because it is targeted at seropositives only and the number of severe dengue cases is
small relative to the total. Only the combination of sustained vector control and immunization
maintains the number of cases at very low levels, for between four and nine years depending
on the country. Again, differences between countries can be explained by differences in the
country-specific epidemiological parameters.
Fig 2. Weekly number of dengue cases with medium or high efficacy sustained vector control technologies but no immunization, best estimates.
https://doi.org/10.1371/journal.pntd.0005785.g002
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The number of cases of severe dengue, however, exhibits a different trend, as can be seen in
Supporting Information S4 Fig. Here, because of our optimistic assumptions about how effec-
tively an immunization strategy could target the seropositive population, we have a large and
sustained effect of immunization, alone and in combination with sustained vector control
(high efficacy). This figure should be interpreted as confirmation that our assumptions about
the immunization strategy have been optimistic.
Table 4 summarizes the average annual number of DALYs in the period 2015–2030 under
different intervention scenarios, compared to WHO Global Health Estimates for the year
2012. Our model suggests that medical case management alone would result in an average of
22.3–232.3 thousand DALYs per year (range of best estimates across the six countries). The
uncertainty intervals on these estimates lie just above WHO estimates for the year 2012, with
the exception of the Philippines (for which our uncertainty interval overlaps with the WHO
estimate). Life expectancy is lower in the Philippines (69 years), than for any of the other
Fig 3. Weekly number of dengue cases with high efficacy sustained vector control and/or a highly targeted immunization strategy, best
estimates.
https://doi.org/10.1371/journal.pntd.0005785.g003
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countries (74–78 years). Note that WHO Global Health Estimates reflect variable levels of
intervention across countries; they are also based on highest observed life expectancy globally.
Outbreak response has a negligible impact on the average burden, given that outbreaks occur
relatively infrequently on average and that the response is triggered only with a lag after the
increase in the vector population. The introduction of sustained vector control (medium efficacy)
reduces the burden to an average of 18.5–167.0 thousand DALYs per year. Sustained vector con-
trol (high efficacy) reduces the burden to an average of 12.0–89.6 thousand DALYs per year.
Costs and affordability
Average annual costs over the 15-year period are reported in Table 5. At current prices of exist-
ing technologies, the total cost of sustained vector control (using a high efficacy technology)
including outbreak response and medical case management (2013 $US 58.0–377.6 million,
range of best estimates across the six countries) is comparable to what would have to be spent
on outbreak response and medical case management (2013 $US 57.7–368.7 million). This
result is driven by differences in the cost of treating the cases that would not be averted by out-
break response, given a minimum one week lag between the increase in vector populations
and deployment of the outbreak response.
In Table 5, the best estimates of cost are expressed also as a percentage of government
health expenditure (GHE) in 2013. Sustained vector control (high efficacy) including medical
Table 4. Average annual DALYs (in thousands) implied by the model (best and 95% uncertainty interval).
Country Burden of disease1 Medical case
management only
Outbreak response Sustained vector control
(medium efficacy
technology)
Sustained vector control
(high efficacy
technology)
Best Best Low High Best Low High Best Low High Best Low High
BRA 103.0 232.3 99.4 539.7 232.2 98.9 537.2 167 18.6 427.5 89.6 1.4 341
COL 9.9 35.6 12.6 93 35.3 12.5 92.3 27.5 5.3 76.4 16.6 0.2 62.3
MEX 5.4 23.9 7.9 62.2 23.7 7.9 61 19.2 4.9 51.3 12 0.1 40.9
MYS 8.4 22.3 9.5 50.4 22.1 9.5 50.4 18.5 5 43.1 12.7 0.2 35
PHL 94.6 58.5 28.2 116.3 58.4 28.1 116.3 48.1 15.5 100 32.9 0.6 86.7
THA 9.5 26.6 9.5 67 26.4 9.4 66.9 20.2 4.2 52.7 11.9 0.2 41
1 WHO’s Global Health Estimates (2014) for the year 2012 [76].
Brazil (BRA), Colombia (COL), Mexico (MEX), Malaysia (MYS), Philippines (PHL) and Thailand (THA).
https://doi.org/10.1371/journal.pntd.0005785.t004
Table 5. Average annual cost and affordability, 2013 US$ millions.
Country Medical case management only Outbreak response Sustained vector control
(high efficacy technology)
Best Low High % of GHE1 Best Low High % of GHE1 Best Low High % of GHE1
BRA 108 33.5 362.2 0.1 368.7 203.8 731.2 0.4 377.6 206.9 721.7 0.4
COL 74.3 22.6 234.6 0.4 124.1 49.4 293 0.6 105.5 37.8 253.7 0.5
MEX 175 50.2 591.9 0.5 326.6 121.3 808.2 0.9 276.3 104.7 698.4 0.7
MYS 43.6 16.3 104.5 0.6 86.9 42.4 156.7 1.3 84.5 38.1 151.7 1.2
PHL 66.2 27.3 158.1 1.8 148.1 75.9 255.2 4 149.5 70.1 271 4
THA 24.4 10.2 62.2 0.2 57.7 30.4 102.6 0.4 58 29.1 104.5 0.4
1 Best estimate divided by Government Health Expenditure (GHE).
Brazil (BRA), Colombia (COL), Mexico (MEX), Malaysia (MYS), Philippines (PHL) and Thailand (THA).
https://doi.org/10.1371/journal.pntd.0005785.t005
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case management would cost 0.4–1.2% of GHE in five of the six countries. In the Philippines,
where GHE in 2013 was much lower in per capita terms than for the other five countries, it
would cost 4.0% of GHE.
Cost-effectiveness
Average cost-effective ratios (ACERs) and incremental cost-effectiveness ratios (ICERs) are
presented for each country in Tables 6 and 7, considering high- and medium-efficacy vector
control technologies, respectively.
If sustained vector control is effective in reducing mosquito populations by 70–90% (high-
efficacy, Table 6), the average cost per DALY averted would be US$ 679–1331 (range of best
estimates across the six countries) relative to the null scenario. The combination of high-effi-
cacy sustained vector control and a highly targeted and low-cost immunization strategy using
a medium-efficacy vaccine dominates all other interventions except immunization alone.
However, immunization alone averts far fewer DALYs. In five of the six countries, the combi-
nation of vector control and immunization is very cost-effective, with an ICER well below one
times GDP per capita. In the Philippines, it is cost-effective at a threshold just above one times
GDP per capita. Recall that the Philippines is the country with the lowest life expectancy
among the six; it is also the country with lowest GDP per capita, and therefore the country
with the (presumed) lowest willingness-to-pay (WTP).
If vector control is effective in reducing mosquito populations by only 50–70%
(medium-efficacy, Table 7), the average cost per DALY averted would be US$ 808–1907
(range of best estimates across the six countries) relative to the null scenario. Again, the
combination of medium-efficacy sustained vector control and a highly targeted and low-
cost immunization strategy using a medium-efficacy vaccine dominates all other interven-
tions except immunization alone. However, again, immunization alone averts far fewer
DALYs. In four of the six countries, the combination of medium-efficacy vector control
and immunization is very cost-effective (the ICER is below one times GDP per capita). In
Mexico and the Philippines it is cost-effective at thresholds between two and three times
GDP per capita. Mexico is the country with the lowest reported death rate among severe
dengue cases receiving medical management.
Uncertainty around cost-effectiveness is reflected in the cost-effectiveness acceptability
curves of Figs 4 and 5. The combination of high-efficacy sustained vector control and a highly
targeted and low-cost immunization strategy using a medium efficacy vaccine (Fig 4) has the
highest probability of being most cost-effective at WTP thresholds as low as one quarter of
GDP per capita (per DALY averted). At a WTP threshold of one times GDP per capita, the
probability that this is the most cost-effective strategy exceeds 85% in four of the six countries.
Discussion
We estimated the cost and cost-effectiveness of sustained vector control in six high-burden
countries. Our model suggests that, at current prices, the cost of sustained vector control and
medical case management is comparable to what would otherwise have to be spent on out-
break response and medical case management. In December 2015, in its decision to approve
Dengvaxia, Mexico reported that it was spending about 2.5% of its health budget on medical
treatment alone [77]. Many countries have abandoned or lack effective surveillance systems to
respond rapidly enough to outbreaks to make much of a dent in the number of cases requiring
medical management [78].
Our results on cost are nonetheless conservative relative to an earlier review and qualitative
synthesis of the evidence from single settings, which found that the cost of outbreak response
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exceeds that of sustained vector control [79]. We considered only direct medical costs and con-
trol programme costs–we did not consider direct non-medical costs faced by patients during
Table 6. Best estimates of costs, DALYs, Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER), high efficacy
vector control over 15 years.
Country
(GDP pc 2013 US
$)
Intervention Costs (2013 US$
millions)
DALYs
(thousands)
ACER (2013 US
$)
ICER (2013 US
$)
BRA (10958) No intervention 0 6158.8 NA NA
Medium efficacy vaccine 1208.6 1967.7 288 288
Case management 1620.5 3484.4 606 Dominated
Medium efficacy vaccine and high efficacy vector
control
5328.8 369.5 920 2578
Just outbreak control 5530.3 3483 2067 Dominated
High efficacy vector control 5664.2 1343.4 1176 Dominated
COL (7831) No intervention 0 1437.9 NA NA
Medium efficacy vaccine 918.1 336.4 834 834
Case management 1115.2 534 1234 Dominated
Medium efficacy vaccine and high efficacy vector
control
1349.3 80.6 994 1685
High efficacy vector control 1582.2 249.3 1331 Dominated
Just outbreak control 1861.1 529.8 2049 Dominated
MEX (11224) No intervention 0 3766 NA NA
Medium efficacy vaccine 2152.6 247.7 612 612
Case management 2625.7 358.9 771 Dominated
Medium efficacy vaccine and high efficacy vector
control
3644 87.1 991 9288
High efficacy vector control 4144.3 179.9 1156 Dominated
Just outbreak control 4899 355.7 1437 Dominated
MYS
(10429)
No intervention 0 1422.9 NA NA
Medium efficacy vaccine 550 236.5 464 464
Case management 654.3 334.1 601 Dominated
Medium efficacy vaccine and high efficacy vector
control
1137.5 72.9 843 3591
High efficacy vector control 1267.2 190.6 1028 Dominated
Just outbreak control 1302.8 331.8 1194 Dominated
PHL (2792) No intervention 0 3794.8 NA NA
Medium efficacy vaccine 819.1 608.1 257 257
Case management 992.6 878.2 340 Dominated
Medium efficacy vaccine and high efficacy vector
control
2024.5 186.3 561 2857
Just outbreak control 2221.5 875.5 761 Dominated
High efficacy vector control 2242.6 493.1 679 Dominated
THA (5879) No intervention 0 1065.6 NA NA
Medium efficacy vaccine 289 245.4 352 352
Case management 365.4 398.9 548 Dominated
Medium efficacy vaccine and high efficacy vector
control
795.6 53.4 786 2639
Just outbreak control 866.1 396.5 1294 Dominated
High efficacy vector control 869.4 179.1 981 Dominated
Brazil (BRA), Colombia (COL), Mexico (MEX), Malaysia (MYS), Philippines (PHL) and Thailand (THA).
https://doi.org/10.1371/journal.pntd.0005785.t006
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their care (e.g. food, transportation) nor any productivity losses (time spent away from work)
of the patients or their caretakers.
Table 7. Best estimates of costs, DALYs, Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER), medium effi-
cacy vector control over 15 years.
Country
(GDP pc 2013
US$)
Intervention Costs (2013 US$
millions)
DALYs
(thousands)
ACER (2013 US
$)
ICER (2013 US
$)
BRA (10958) No intervention 0 6158.8 NA NA
Medium efficacy vaccine 1208.6 1967.7 288 288
Case management 1620.5 3484.4 606 Dominated
Just outbreak control 5530.3 3483 2067 Dominated
Medium efficacy vaccine and medium efficacy
vector control
5731.7 917.9 1094 4309
Medium efficacy vector control 6189.6 2504.8 1694 Dominated
COL (7831) No intervention 0 1437.9 NA NA
Medium efficacy vaccine 918.1 336.4 834 834
Case management 1115.2 534 1234 Dominated
Medium efficacy vaccine and medium efficacy
vector control
1667.7 175.7 1321 4664
Just outbreak control 1861.1 529.8 2049 Dominated
Medium efficacy vector control 1954.4 412.9 1907 Dominated
MEX (11224) No intervention 0 3766 NA NA
Medium efficacy vaccine 2152.6 247.7 612 612
Case management 2625.7 358.9 771 Dominated
Medium efficacy vaccine and medium efficacy
vector control
4308.9 151 1192 22309
Just outbreak control 4899 355.7 1437 Dominated
Medium efficacy vector control 4995.2 287.4 1436 Dominated
MYS
(10429)
No intervention 0 1422.9 NA NA
Medium efficacy vaccine 550 236.5 464 464
Case management 654.3 334.1 601 Dominated
Medium efficacy vaccine and medium efficacy
vector control
1274.7 139.8 994 7499
Just outbreak control 1302.8 331.8 1194 Dominated
Medium efficacy vector control 1426.1 277.7 1245 Dominated
PHL (2792) No intervention 0 3794.8 NA NA
Medium efficacy vaccine 819.1 608.1 257 257
Case management 992.6 878.2 340 Dominated
Just outbreak control 2221.5 875.5 761 Dominated
Medium efficacy vaccine and medium efficacy
vector control
2241 357.5 652 5673
Medium efficacy vector control 2484.1 721.7 808 Dominated
THA (5879) No intervention 0 1065.6 NA NA
Medium efficacy vaccine 289 245.4 352 352
Case management 365.4 398.9 548 Dominated
Just outbreak control 866.1 396.5 1294 Dominated
Medium efficacy vaccine and medium efficacy
vector control
886.5 124.6 942 4946
Medium efficacy vector control 982.9 303.6 1290 Dominated
Brazil (BRA), Colombia (COL), Mexico (MEX), Malaysia (MYS), Philippines (PHL) and Thailand (THA).
https://doi.org/10.1371/journal.pntd.0005785.t007
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Our estimates of the cost per DALY averted by sustained vector control (related to doing
nothing) are lower than that of the DCP2, but higher than those from studies of single settings.
In those studies, cost-effectiveness ratios ranged from 2005 US$ 227 (2013 US$ 344) per
DALY averted by larval control in Cambodia to 2009 US$ 615–1267 (2013 US$ 802–1652) per
DALY averted by adult mosquito control in Brazil [9][10]. Taking a broader societal perspec-
tive including productivity losses, the Cambodia programme cost only 2005 US$ 37 (2013 US$
56) per DALY averted. Again, we did not consider these productivity losses–their measure-
ment remains controversial, although few would argue that they are zero.
We have not (nor to our knowledge has any earlier study) considered the additional bene-
fits of vector control targeted at dengue for the prevention of other diseases, such as Chikungu-
nya, yellow fever and Zika fever, transmitted by the same vectors and (for all but yellow fever)
lacking effective vaccines and specific treatment. These additional benefits of sustained vector
Fig 4. Probability of being most cost-effective at any given threshold, considering high-efficacy sustained vector control and a highly targeted,
low-cost immunization strategy. The solid lines are cost-effectiveness acceptability curves (CEACs) representing the probability that an intervention is
cost-effective at a given threshold; the (vertical) dashed line indicates the probability that an intervention is cost-effective at a threshold equal to GDP per
capita; the dotted line represents the cost-effectiveness acceptability frontier (CEAF) which represents the probability that the most cost-effective option is
cost-effective at a given threshold.
https://doi.org/10.1371/journal.pntd.0005785.g004
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control would increase its cost-effectiveness. Even with conservative assumptions, our results
suggest that sustained vector control can be highly cost-effective.
Our model suggests that the introduction of highly targeted and low-cost immunization
strategy using a medium-efficacy vaccine does not alter the conclusion that sustained vector
control can be highly cost-effective. On the contrary, vector control may complement a
medium-efficacy vaccine, or a vaccine that is highly effective but against only secondary infec-
tions or only one of the four dengue serotype, or whose production is highly constrained. In
these instances, sustained vector control may compensate to some extent for lower levels of
coverage by immunization.
There are as yet no costing studies for dengue vaccine delivery, nor even a known price for
the vaccine itself [77][80][81]. Indeed, there are still many unknowns about immunization for
dengue. Overall, our assumptions for immunization can be considered conservative from the
Fig 5. Probability of being most cost-effective at any given threshold, considering medium-efficacy sustained vector control and a highly
targeted, low-cost immunization strategy. The solid lines are cost-effectiveness acceptability curves (CEACs) representing the probability that an
intervention is cost-effective at a given threshold; the (vertical) dashed line indicates the probability that an intervention is cost-effective at a threshold equal
to GDP per capita; the dotted line represents the cost-effectiveness acceptability frontier (CEAF) which represents the probability that the most cost-effective
option is cost-effective at a given threshold.
https://doi.org/10.1371/journal.pntd.0005785.g005
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perspective of the cost-effectiveness of sustained vector control. That is, we have been optimis-
tic in our assumptions about immunization with regard to both effects and costs, in order to
have the most conservative estimate of the cost-effectiveness of vector control in the presence
of immunization. We have been particularly optimistic in assuming that the targeting strate-
gies for immunization are perfectly effective in avoiding seronegative people. This analysis
should not, therefore, be used to draw conclusions about the cost-effectiveness of the current
vaccine. When new information or new vaccines become available, these model parameters
should be adapted.
We accounted for many of the known sources of uncertainty within a probabilistic frame-
work. In spite of considerable uncertainty, sustained vector control emerged with a high prob-
ability of cost-effectiveness. Some sources of uncertainty, however, could not be accounted for
and remain as more serious limitations to our study.
First, there is remaining uncertainty around particular parameter values. The serotype
immunity variable (serotype composition) is assumed to be constant over time. The probabil-
ity that dengue fever following a second infection develops into severe dengue is based on clin-
ical paediatric data from four hospitals [39]. While the probability of death among severe
dengue cases receiving medical management was based on country-reported data, the consid-
erable disparity across countries raises questions. The availability of better data for these
parameters would improve the precision of our model.
Second, there is remaining uncertainty about the structure of the model itself, namely with
respect to outbreaks, which are modelled as increases in the vector population. Vector indices
have been correlated to increases in dengue cases during outbreaks, but the strength of evi-
dence is limited by a lack of well-controlled studies [82][83]. Other studies have considered
spatial, meteorological, epidemiological, and entomological factors, and dengue serotype [84].
Although this study could benefit from a more sophisticated outbreak model, uncertainty
remains in the choice of variables and availability of data.
Another limitation of the model structure is that we have not modelled heterogeneity in
transmission. The probability of contracting dengue assumes an even distribution of vectors to
humans throughout the susceptible population. However, a study from Armenia and Colom-
bia found that 95% of Ae aegytpi pupae were concentrated in only 5% of houses [85]. More
detailed risk mapping could improve our analysis and lead to better targeting and enhanced
cost-effectiveness of vector control.
Third, we have made no assumptions about the relative costs of the different vector control
technologies–in fact, we have assumed the same unit cost for both medium- and high-efficacy
technologies. Obviously, this analysis does not help us to choose amongst available vector con-
trol technologies. Further research is needed to understand the drivers of cost and effect across
current and future vector control technologies. Indeed, it is unclear whether reductions in
excess of 70–90% can be sustained using existing technologies; more research on the long-
term impact of both existing and upcoming technologies is needed.
Nonetheless, the result on the cost-effectiveness of high-efficacy vector control is fairly
robust to higher unit costs. Comparing ICERs to WTP, we find that in most settings, the cost
of sustained vector control using high-efficacy technologies could be considerably higher than
that assumed in our model (about US$ 0.05 per capita per month) before it would no longer
be considered cost-effective. At a WTP threshold of three times GDP per capita, the cost could
be as much as 2.9–13.9 times higher without affecting our conclusions for any of the settings
considered. At a WTP threshold of one times GDP per capita, the cost could be as much as
2.2–4.6 times higher without affecting our conclusions for Brazil, Colombia, Malaysia, and
Thailand.
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Fourth, our model does not reflect uncertainty around the impact of resistance to insecti-
cides in a scenario of sustained vector control. The data on this are limited, as a result of poor
routine resistance monitoring [86]. New vector control technologies, such as genetic modifica-
tion or symbiont infection of vectors, once developed, may help in mitigating the risk of resis-
tance [87]. Our results are favourable to sustained vector control in general (not to any one
technology in particular) and should not discourage the development of new technologies
with demonstrated efficacy and safety. Indeed, our results apply to any technology that reduces
the number of vectors able to transmit disease, rather than the number of vectors per se.
Finally, our results may not be generalizable to other settings, for which we do not have
good epidemiological or cost data. Low-income countries, especially those in Africa, are argu-
ably more vulnerable and less prepared for the effects of unplanned urbanization and climate
change, including the spread of vector-borne diseases [88]. These same countries have the
poorest quality data on dengue, starting with the frequent misclassification of dengue as
malaria. A regional study of the cost and cost-effectiveness of sustained vector control in low-
income countries of Africa is needed.
This paper focussed on the cost-effectiveness of sustained vector control in six middle-
income endemic countries representing 15% of the estimated global burden of dengue. We
have shown that sustained vector control will be cost-effective in most of these countries if it
succeeds in reducing mosquito populations by more than 50%. Importantly, we show that the
introduction of a highly targeted and low-cost immunization strategy using a medium-efficacy
vaccine does not weaken the investment case for sustained vector control. Middle-income
endemic countries should proceed with mapping the populations to be covered by sustained
vector control.
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